The CDDF is governed by a rotating board of directors dedicated to the development of cancer drugs. These distinguished academics are experienced pre-clinical and clinical investigators, medical oncologists, statisticians, and immunologists representing a range of perspective within the drug development process. They have experience working within regulatory agencies, the pharmaceutical industry and patient advocacy. The chairperson and directors are elected for a period of three years. The CDDF board of directors aim to speed up and optimise drug development programmes and avoid suboptimal drug development strategies.
CDDF BOARD OF DIRECTORS
- Prof. John Smyth – Chairperson (2019 to Nov 2022)
- Prof. Ruth Plummer – Vice-Chairperson
- Prof. Eva Skovlund
- Prof. Axel Glasmacher –Treasurer
- Prof. Jaap Verweij – Managing Director
- Prof. Francesco De Lorenzo
- Dr. Catarina Edfjäll
- Prof. Mark Lawler
- Dr. Katrin Rupalla
- Prof. Stefan Symeonides
CDDF OFFICE
- Prof. Jaap Verweij – Managing Director
- Marjorie Recorbet -Director of Operations
- Magdalena Strmenova – Event Coordinator
- Giorgia Campagnano – Event Coordinator
CDDF staff members oversee the day to day running of the organisation. The head office is located in Brussels, Belgium.